Drug firm Eli Lilly and Company Thursday said it has entered the autoimmune segment in India with launch of Olumiant, a new once-daily oral therapy for treatment of rheumatoid arthritis.
Olumiant is approved in more than 50 countries across the world, it said.
"Lilly India is excited to announce the introduction of its innovative therapy for patients living with rheumatoid arthritis," Eli Lilly and Company (India) MD Luca Visini said.
Olumiant is an effective, advanced once-daily oral treatment option for people suffering from rheumatoid arthritis who have not responded well to conventional disease-modifying anti-rheumatic drugs (DMARDs), he added.
The product will be available in India in 4mg and 2mg dosage forms, the company said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app